Gut check: could your microbiome predict immunotherapy success?
NCT ID NCT06050733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the gut bacteria of 16 people with advanced solid cancers who are receiving standard immunotherapy. Researchers will analyze stool samples and cognitive function to see if there is a link between the gut microbiome and how well the treatment works. The goal is to gather knowledge, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand why some patients respond better to immunotherapy based on their gut bacteria.
- What could go wrong
- This is a very small, early observational study with only 16 people. It is not testing a treatment, so it may not lead to any direct changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Medical Branch
RECRUITINGGalveston, Texas, 77845, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?